ECSP16075416A - Anticuerpos de il-21 - Google Patents

Anticuerpos de il-21

Info

Publication number
ECSP16075416A
ECSP16075416A ECIEPI201675416A ECPI201675416A ECSP16075416A EC SP16075416 A ECSP16075416 A EC SP16075416A EC IEPI201675416 A ECIEPI201675416 A EC IEPI201675416A EC PI201675416 A ECPI201675416 A EC PI201675416A EC SP16075416 A ECSP16075416 A EC SP16075416A
Authority
EC
Ecuador
Prior art keywords
antibodies
methods
compositions
conditions
antagonism
Prior art date
Application number
ECIEPI201675416A
Other languages
English (en)
Inventor
S A S Tekquímica
Treasurer Representatives S A Financial
Acuicolas S A Insuaqua Insumos
Lilly And Company Eli
Douglas W Beight
Sajan Joseph
William T Mcmillen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP16075416A publication Critical patent/ECSP16075416A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos humanizados, diseñados por ingeniería que tienen alta afinidad para y neutralizan a IL-21 humana, métodos para usar los anticuerpos para tratar condiciones en las cuales el antagonismo o neutralización de los efectos de IL-21 está garantizado, tales como condiciones autoinmunes, composiciones y métodos para producir recombinantemente los anticuerpos, y composiciones farmacéuticas que comprenden los anticuerpos.
ECIEPI201675416A 2014-03-21 2016-09-20 Anticuerpos de il-21 ECSP16075416A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461968550P 2014-03-21 2014-03-21

Publications (1)

Publication Number Publication Date
ECSP16075416A true ECSP16075416A (es) 2018-05-31

Family

ID=54141466

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201675416A ECSP16075416A (es) 2014-03-21 2016-09-20 Anticuerpos de il-21

Country Status (24)

Country Link
US (1) US9394362B2 (es)
EP (1) EP3119806B1 (es)
JP (2) JP6053989B2 (es)
KR (1) KR101859857B1 (es)
CN (1) CN106061999B (es)
AP (1) AP2016009450A0 (es)
AR (1) AR099625A1 (es)
AU (1) AU2015231777B2 (es)
BR (1) BR112016019176A2 (es)
CA (1) CA2939543C (es)
CL (1) CL2016002281A1 (es)
EA (1) EA033335B1 (es)
EC (1) ECSP16075416A (es)
ES (1) ES2774422T3 (es)
IL (1) IL246909A0 (es)
MA (1) MA39342B2 (es)
MX (1) MX2016012120A (es)
MY (1) MY177915A (es)
NZ (1) NZ722518A (es)
PE (1) PE20161221A1 (es)
PH (1) PH12016501820A1 (es)
SG (1) SG11201606705QA (es)
TW (1) TWI646105B (es)
WO (1) WO2015142637A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
JP2018536650A (ja) * 2015-10-30 2018-12-13 ジェネンテック, インコーポレイテッド 抗d因子抗体変異体コンジュゲート及びその使用
CA3018792C (en) 2016-03-31 2023-03-28 Eli Lilly And Company Il-21 antibodies and uses thereof
US11554131B2 (en) * 2018-05-31 2023-01-17 Glycom A/S Mixture of HMOs for treating autoimmune diseases
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
EP4017594A1 (en) 2019-08-21 2022-06-29 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2024525613A (ja) * 2021-07-09 2024-07-12 ダイン セラピューティクス,インコーポレーテッド 筋標的化複合体およびジストロフィノパチーを処置するためのその使用
US20240318176A1 (en) * 2021-07-09 2024-09-26 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
EP1960433A2 (en) * 2005-11-28 2008-08-27 Zymogenetics, Inc. Il-21 receptor antagonists
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
EP2217268B1 (en) * 2007-12-07 2016-05-04 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
SI2796466T1 (en) * 2007-12-07 2018-01-31 Zymogenetics, Inc. Molecules of Humanized Specifics Specifiable for IL-31
US20130323259A1 (en) 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
WO2012164021A1 (en) * 2011-05-31 2012-12-06 Novo Nordisk A/S Il-21 epitope and il-21 ligands

Also Published As

Publication number Publication date
JP2017093435A (ja) 2017-06-01
JP2016520088A (ja) 2016-07-11
MX2016012120A (es) 2016-12-09
PH12016501820A1 (en) 2016-11-07
TW201623330A (zh) 2016-07-01
KR101859857B1 (ko) 2018-05-18
NZ722518A (en) 2017-12-22
IL246909A0 (en) 2016-09-29
EP3119806A4 (en) 2017-11-01
AU2015231777A1 (en) 2016-08-18
PE20161221A1 (es) 2016-11-12
TWI646105B (zh) 2019-01-01
JP6053989B2 (ja) 2017-01-11
BR112016019176A2 (pt) 2017-10-10
EA201691521A1 (ru) 2017-02-28
SG11201606705QA (en) 2016-09-29
JP6373944B2 (ja) 2018-08-15
AR099625A1 (es) 2016-08-03
EP3119806A1 (en) 2017-01-25
WO2015142637A1 (en) 2015-09-24
CL2016002281A1 (es) 2017-06-23
MA39342B2 (fr) 2020-03-31
US20150266954A1 (en) 2015-09-24
MA39342A1 (fr) 2018-03-30
EP3119806B1 (en) 2020-01-01
CA2939543A1 (en) 2015-09-24
EA033335B1 (ru) 2019-09-30
MY177915A (en) 2020-09-25
AP2016009450A0 (en) 2016-09-30
CN106061999A (zh) 2016-10-26
US9394362B2 (en) 2016-07-19
CN106061999B (zh) 2020-07-31
KR20160124166A (ko) 2016-10-26
ES2774422T3 (es) 2020-07-21
CA2939543C (en) 2018-01-16
AU2015231777B2 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
CL2016002281A1 (es) Anticuerpos de il-21
GT201700188A (es) Anticuerpos contra tau y sus usos
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
CL2018000422A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
PT3889145T (pt) 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
ECSP16073171A (es) Ciclopropilaminas como inhibidores de lsd1
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
EA201691974A1 (ru) Антитела против ox40 и способы их применения
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2017001960A1 (es) Métodos de tratamiento de enfermedades inflamatorias
CO2017001658A2 (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
MX381640B (es) Metodos y compuestos agonistas de gip.
CR20180529A (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada
MX378108B (es) Anticuerpos anti-met y composiciones.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX2017002388A (es) Composiciones para fibras de queratina.
MX2017007338A (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis.